CB Insights
Technology Market Intelligence
Technology Market Intelligence
Public list: Pharma Startups (6570) Cancer Therapeutics (1180)
Theraclone Sciences, formerly Spaltudaq, is a biotechnology company focused on the development of novel therapeutic antibodies for the treatment of infectious disease and cancer. The companys technology harnesses the power of the human immune system ...Show all
Company (Alive / Active)
Phone: 206-805-1600
1124 Columbia Street
Suite 300
Seattle, 98104
Washington, United States
| Total Funding | Date of Last Funding | |
|---|---|---|
| Theraclone Sciences | $63.8M | May 7, 2015 |
| See all 15 competitors | ||
| Per Week | Per Month | Per 6 Months | Per Year | |
|---|---|---|---|---|
| Rank | Login to see details | |||
| Page Views Per Million | Login to see details | |||
| Page Views Per User | Login to see details | |||
| Reach Per Million | Login to see details | |||
| Title | Application Date | Patent Date | Status (Patent / Application) |
|---|---|---|---|
| Monoclonal antibodies directed against trimeric forms of the hiv-1 envelope glycoprotein with broad and potent neutralizing activity | Apr 21, 2015 | Mar 20, 2018 | Patent |
| Broadly neutralizing human immunodeficiency virus type 1 (hiv-1) gp120-specific monoclonal antibody | Feb 28, 2013 | Oct 11, 2016 | Patent |
| Monoclonal antibodies directed against trimeric forms of the hiv-1 envelope glycoprotein with broad and potent neutralizing activity | Mar 17, 2010 | Jun 09, 2015 | Patent |
| Compositions and methods for the therapy and diagnosis of influenza | Aug 12, 2010 | Mar 10, 2015 | Patent |
| Human m2e peptide immunogens | Jun 14, 2012 | Jan 13, 2015 | Patent |
